Galway, 06 April 2021 Veryan has announced a multimillion-euro investment at its Galway facility that will contribute to the further expansion and diversification of Veryan’s product portfolio beyond the BioMimics 3D Swirling Flow stent, marketed in Europe and USA to improve blood flow through arteries in the leg.
Veryan Medical (Horsham, UK) is delighted to announce that the first patient was enrolled today in the MIMICS-3D USA study by John H. Rundback MD at NJ Endovascular & Amputation Prevention, NJ.
Veryan Medical (Horsham, UK) has announced that Dr. Bret Wiechmann and his team at Vascular and Interventional Physicians in Gainesville, FL implanted the first commercial BioMimics 3D Vascular stent in the US, on the same day that the device was officially launched in the US. The BioMimics 3D self-expanding, nitinol stent features a highly differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up, MIMICS-2.
Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly-differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up.
Walk Vascular, LLC (Irvine, CA) and Veryan Medical (Horsham, UK) have announced that from today Veryan Medical will support Walk Vascular in the commercialization of the innovative JETi Peripheral Thrombectomy System in Germany.
Professor Thomas Zeller (University Heart Centre Freiburg, Bad Krozingen, Germany) today presented the 36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live.
Veryan Medical press release on completion of MIMICS 3D enrollment. 20th June 2018